Page 14 of 20
OP7.5 | Glaucoma Treatment Counselling and Prognosis Discussion — SDL Guide (Part 2)
Reading the Patient: Adherence Barriers and Responses
Every experienced glaucoma clinician knows that the principal predictor of long-term outcomes is not the choice of first-line drug or the target IOP — it is whether the patient actually uses the treatment consistently. Adherence to glaucoma drops is notoriously poor for systemic reasons that are not unique to glaucoma but are amplified by its silent nature. Identifying a patient's specific barrier — not assuming a generic response — and responding with a tailored explanation is the hallmark of effective counselling.
The five commonest adherence barriers in glaucoma, with evidence-based responses:
Barrier 1: 'I don't feel anything wrong — why do I need drops?'
This is the most common barrier, arising from the disconnect between objective disease severity and subjective experience. The response: explain the silent nature of nerve damage using an analogy the patient can grasp — 'Glaucoma is like high blood pressure: you can't feel high blood pressure, but it silently damages blood vessels and can cause a stroke. Similarly, you can't feel the raised pressure in your eye, but it is silently damaging your optic nerve. The damage happens so slowly that by the time you notice something wrong, a large part of the nerve has already been lost — and that damage is permanent. Treatment keeps the pressure low to prevent that damage from happening, even though you feel no different with or without the drops.'
Barrier 2: Side effects (redness, eyelash changes, cosmetic concerns)
Patients often stop prostaglandin analogues because of mild hyperaemia or they notice eyelash changes. The response: acknowledge the side effect is real; contextualise its significance; offer alternatives. 'The redness is the most common side effect of latanoprost. It usually settles after the first few weeks. If it persists, we can try a different prostaglandin formulation (travoprost or preservative-free preparations) or add a different type of drop. The eyelash thickening is cosmetically benign — many patients actually don't mind it. Stopping the drop because of these minor effects risks your vision progressing.'
Barrier 3: Cost of branded medications
In India, branded latanoprost can cost ₹200–600 per bottle (approximately one month's supply). Generic latanoprost is available at much lower cost. The response: 'There are generic versions of this drop that are equally effective and much less expensive. I can prescribe the generic — let me write the generic name for you. NPCBVI (the National Programme for Control of Blindness and Visual Impairment) also supplies glaucoma medications at government hospitals — you can ask at the district hospital pharmacy.'
Barrier 4: Forgetting the dose / poor regimen understanding
Many patients on multiple drops confuse the timing. The response: simplify and anchor drops to existing routines. 'Latanoprost is once a day, always in the evening — you can link it to brushing your teeth at night. Put the bottle next to your toothbrush as a reminder. If you're on multiple drops, I'll give you a simple written schedule with morning and evening drops listed separately.'
Barrier 5: 'Why don't I just have the operation and be done with it?'
Patients sometimes prefer surgical resolution to lifelong drops. The response: explain that surgery is effective but not without risk, and is reserved for when drops are insufficient. 'Surgery — the operation called trabeculectomy — is very effective at lowering eye pressure. But it carries risks: infection, low pressure causing blurry vision, and it can speed up cataract formation. We prefer to use surgery when drops and laser are not enough, because the risks are real and we want to minimise them. At your current stage of disease, drops are the right first step, and they work well in most patients.'
| Barrier | Clinician Response Strategy |
|---|---|
| 'No symptoms — why bother?' | Silent nerve damage analogy; irreversibility message; protective framing |
| Side effects (redness, lashes) | Validate; contextualise; offer alternatives (generic, preservative-free, different drug) |
| Cost | Generic prescribing; NPCBVI programme; explain bioequivalence |
| Forgetting/confusion | Anchor to routine; written schedule; pill reminder app |
| 'Why not just operate?' | Explain surgery is reserved for inadequate medical control; describe realistic risks |
CLINICAL PEARL
The single most powerful phrase in glaucoma counselling is: 'The drops do not make your vision better — they prevent it from getting worse. What you are protecting by using these drops is the vision you still have.' Patients frequently discontinue therapy because they notice no improvement, expecting the drops to 'fix' their sight. Explicitly setting this expectation at the first consultation — that treatment is protective, not curative — prevents the most common reason for early discontinuation. A corollary: when counselling about prognosis, always separate 'the vision already lost' (irreversible) from 'the vision you still have' (protectable with good IOP control). This framing gives the patient a clear, positive rationale for ongoing treatment while being fully honest about the disease.
Applied Practice: Three Counselling Scenarios
The following three worked scenarios build practical competence in the key counselling situations a final-year student or junior doctor will encounter. Each scenario identifies the key messages, the likely patient response, and the recommended clinician approach. Reading through these scenarios is not a passive exercise — at each decision point, pause and consider what you would say before reading the suggested response. Effective glaucoma counselling cannot be scripted verbatim; it must be internalised as a flexible framework that you adapt to the individual patient's language, health literacy, emotional state, and specific concerns. The three scenarios below represent the three most high-stakes counselling encounters you will face: the newly diagnosed asymptomatic POAG patient who does not understand why they need drops; the patient who has just survived an acute PACG attack and needs to understand why their unaffected fellow eye also requires laser treatment; and the patient with advanced glaucoma who must be told honestly that the vision already lost cannot be recovered, while being motivated to protect what remains. Mastery of these three conversations prepares you for the vast majority of real-world glaucoma counselling situations, and for the structured OSCE station in which a simulated patient will test your ability to communicate accurately, empathetically, and effectively.
Scenario A — Newly diagnosed POAG: Mr. Rajan, 60 years
Setting: First clinic visit. IOP 26 mmHg, C:D 0.7, early arcuate scotoma. No symptoms.
Key messages to deliver:
1. What glaucoma is: raised eye pressure slowly damaging the optic nerve
2. Why treatment is needed despite feeling well: silent damage; irreversible if untreated
3. What latanoprost is: one drop each evening in both eyes; mechanism: helps fluid drain
4. Side effects: mild redness, eyelash changes, iris colour change in hazel eyes (irreversible — important to mention before starting)
5. Prognosis: with good IOP control, most patients preserve useful vision throughout their lives
6. Follow-up: 4–6 weeks for IOP check; lifelong monitoring
Likely patient response: 'My brother has glaucoma too — does this mean my children are at risk?' → YES: first-degree relatives have 4× increased risk; advise them to have IOP and disc checked from age 35.
Scenario B — Post-acute PACG: Mrs. Krishnamurthy, 55 years
Setting: Day 3 after an acute angle-closure attack in the right eye. IOP has been controlled. Gonioscopy confirms narrow occludable angle bilaterally.
Key messages to deliver:
1. What caused the attack: the drainage angle in her eye suddenly blocked; fluid couldn't drain; pressure shot up
2. What LPI does: the laser makes a tiny hole in the iris; this gives the fluid an alternate escape route so the angle can never block again
3. Why the LEFT eye also needs treatment: 'Your left eye has exactly the same narrow angle as your right eye — without treatment, it has a very high chance of having a similar attack. We need to do the same laser procedure on your left eye prophylactically.'
4. Precipitants to avoid: dim light environments, anticholinergic drugs (antihistamines, bladder medications, tricyclic antidepressants) — ask the pharmacist before starting any new medication
5. Prognosis of the treated eye: if the acute attack has not caused significant optic nerve damage, the prognosis is excellent after LPI. If disc damage occurred during the attack, ongoing monitoring for progression is needed.
Likely patient concern: 'Will I need drops after the laser?' → Possibly: LPI eliminates the pupil-block mechanism, but if the trabecular meshwork has been damaged by the attack (from high IOP or PAS formation), IOP may remain elevated and drops may still be needed.
Scenario C — Advanced POAG: Mr. Mohan, 68 years
Setting: Patient presents with advanced binocular glaucoma. IOP has been poorly controlled (non-adherent to drops). Visual fields show tunnel vision in both eyes. Surgical discussion is needed.
Key messages to deliver:
1. Acknowledge the vision loss directly but compassionately: 'Mr. Mohan, I want to be honest with you about what I see in today's test — the field loss in both eyes is significant. I know this is difficult news.'
2. Explain what cannot be recovered: 'The visual field that has already been lost cannot be restored — no drops or surgery can recover it. This is why I am concerned.'
3. Explain what can be protected: 'The vision you still have — your central vision, your ability to read, to recognise faces — can be preserved with good pressure control. This is what we must focus on.'
4. Recommend surgery and explain why: 'At this stage, drops alone are not enough. I recommend trabeculectomy — an operation that creates a permanent new drainage pathway. The goal is to get your eye pressure low enough to stop any further damage to the central vision.'
5. Address emotional impact: acknowledge frustration or grief about vision loss; ask if the patient would like to have a family member present; provide referral to low vision rehabilitation if central acuity is affected.
Communication principle: Separate the two messages clearly — 'what is already lost' and 'what we are fighting to protect' — and make sure the patient leaves with the second message as the primary frame of action.
SELF-CHECK
After an acute PACG attack in the right eye treated with IV mannitol, IV acetazolamide, and pilocarpine, a 56-year-old patient's IOP is now controlled. She asks: 'Why do I need a laser in my other eye when that eye is perfectly fine?' Which explanation is most accurate and patient-centred?
A. 'Because glaucoma always affects both eyes, and your left eye already has the disease.'
B. 'Your left eye has the same narrow angle anatomy as your right eye. Without a laser, it has a high risk of having the same sudden attack. The laser creates a tiny hole in the iris to prevent that from happening.'
C. 'The laser in the left eye will lower the pressure and prevent you needing drops.'
D. 'It is just routine — we do it to all glaucoma patients regardless.'
Reveal Answer
Answer: B. 'Your left eye has the same narrow angle anatomy as your right eye. Without a laser, it has a high risk of having the same sudden attack. The laser creates a tiny hole in the iris to prevent that from happening.'
Option B is accurate and patient-centred: it explains the anatomical basis (same narrow angle in both eyes), states the specific risk (high chance of an acute attack in the fellow eye), and explains the mechanism of LPI (tiny hole to prevent pupil block). Option A is inaccurate — the left eye may not yet have glaucoma (just predisposed to angle closure). Option C is inaccurate — LPI does not primarily lower the pressure (it eliminates pupil block); drops may still be needed. Option D is dismissive and non-explanatory.
Self-Assessment: Counselling Competence Challenges
Having worked through the indication, conceptual toolkit, technique, and applied scenarios of glaucoma counselling, you are now ready to test your readiness for the OSCE and for real clinical encounters through self-directed reflection and challenge questions.
Challenge 1 — The resistive patient: A 58-year-old man with moderate POAG has been on latanoprost for 18 months. At every review his IOP remains at 24 mmHg (target: 17 mmHg). He insists he is using the drops daily. His bottle is always nearly full. What do you do? First, explore barriers non-judgementally: 'I notice your bottle is quite full — sometimes people find it hard to use drops every day. Can you walk me through what you do?' Poor technique (missing the eye), forgetting evening doses, and deliberate non-use (because of side effects he has not disclosed) are all common. Teach-back the technique in front of you. If adherence is genuinely problematic, offer selective laser trabeculoplasty as an alternative that removes the daily compliance burden. Document the conversation.
Challenge 2 — The informed family member: A 45-year-old woman comes in because her father was just diagnosed with POAG. She has no symptoms and her IOP is 18 mmHg. She asks: 'Do I need treatment?' Explain that first-degree relatives of POAG patients have a 4-fold increased risk. She does not currently have glaucoma (IOP normal, discs need assessment, fields needed). She needs a full glaucoma screening evaluation — optic disc assessment, CCT, gonioscopy, and baseline perimetry. If all normal, she needs annual monitoring from now. She does not need treatment today, but she should never miss her annual check.
Challenge 3 — Prognosis after a difficult conversation: A 72-year-old woman with advanced bilateral POAG (tunnel vision, IOP poorly controlled despite trabeculectomy) asks: 'Am I going to go blind, doctor?' Using the prognosis communication framework: be honest (her disease is advanced and her remaining visual field is narrow), be hopeful (her central vision is still present, and aggressive IOP control now can slow progression significantly), and focus on agency (her adherence to treatment and follow-up is the most powerful predictor of how quickly the remaining field is lost). Do not offer false reassurance, but do not withdraw all hope. Offer low vision rehabilitation referral proactively — magnifiers, large-print resources, mobility training — so she is supported whatever the trajectory.